Asano Shogo, Suzuki Atsushi
Toyokawa City Hospital, Toyokawa, Aichi, Japan.
Clin Calcium. 2013 Mar;23(3):401-8.
Glucocorticoid-induced osteoporosis (GIOP) is known as a serious adverse side effect during long-term glucocorticoid treatment. Several clinical guidelines are available to whom and how we should start to treat GIOP. However, the assessment of the treatment of GIOP is still controversial. Accumulating evidences suggest us that both bone mineral density and bone turn over markers could reflect the effect of some pharmacological agents on bone metabolism. However, further studies would be required for precise assessment of the efficacy of drugs on fracture prevention in GIOP.
糖皮质激素性骨质疏松症(GIOP)是长期糖皮质激素治疗期间已知的一种严重不良副作用。有若干临床指南可供参考,指导我们应该对谁以及如何开始治疗GIOP。然而,对GIOP治疗的评估仍存在争议。越来越多的证据表明,骨密度和骨转换标志物都可以反映某些药物对骨代谢的影响。然而,需要进一步研究以精确评估药物对GIOP骨折预防的疗效。